Renal or hepatic impairment, often encountered in patients with type 2 diabetes, influences
the pharmacokinetics and bioavailability of antihyperglycemic agents. An emerging concern …

Аннотация Современная диабетология обращает самое серьезное внимание на
метаболизм жировой ткани потому, что жировая ткань очень тесно связана с …

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in patients
with type 2 diabetes. However, the effect on abdominal obesity has not yet been confirmed …

Mitochondrial dysfunction is associated with cardiovascular diseases and diabetes.
Pulmonary arterial hypertension (PAH) is characterized by pulmonary vascular remodeling …

High calorie diet promotes oxidative stress and chronic low grade inflammation that
predispose to brain dysfunction and neurodegeneration. Hippocampus region of the brain …

Background Effects of the new class of anti-diabetic drugs, sodium-glucose cotransporter 2
(SGLT2) inhibitors, on metabolic parameters in patients with type 2 diabetes remain largely …

Maternal obesity programs the offspring to metabolic diseases later in life; however, the
mechanisms of programming are yet unclear, and no strategies exist for addressing its …

Current gold standard therapeutic strategies for T2DM target insulin resistance or β cell
dysfunction as their core mechanisms of action. However, the use of traditional anti-diabetic …

AIM: To investigate the mechanism and in vivo effects of MK-0626, a dipeptidyl peptidase-4
inhibitor, on hepatic steatosis using ob/ob mice. METHODS: We analyzed obese (ob/ob) 8 …

Abstract Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and inhibits glucagon
secretion in the pancreatic islets of Langerhans under hyperglycaemia. In type 2 diabetes …